Ocrevus (ocrelizumab)

Prescribing Information

Safety Data Sheets:

OCREVUS^® Vials (300 mg/10 mL)

Our Commitment to Safety

Visit ocrelizumabinfo.com, a different Genentech medical website, for key Ocrevus^® safety topics

Visit Site

Publications and Congresses Clinical Trials
Additional Resources

Publications

Visit PubMed.gov to browse a listing of published scientific literature about Ocrevus^®.

Ocrelizumab versus placebo in primary progressive multiple sclerosis
Montalban X, Hauser SL, Kappos L, et al. N Engl J Med 2017;376(3):209-220.

VIEW

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
Bar-Or A, Calkwood JC, Chognot C, et al. Neurology 2020;95(14):e1999-e2008.

VIEW

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Hauser SL, Bar-Or A, Comi G, et al. N Engl J Med 2017;376(3):221-234.

VIEW

Shorter infusion time of ocrelizumab: results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
Hartung HP, Berger T, Bermel RA, et al. Mult Scler Relat Disord 2020;46:102492.

VIEW

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.